Manuel Mateo Perez Encinas
Overview
Explore the profile of Manuel Mateo Perez Encinas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
96
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang Y, Wei C, Lin C, Gurnari C, Awada H, Benajiba L, et al.
Leukemia
. 2024 Oct;
39(1):144-154.
PMID: 39367172
In addition to high-molecular risk (HMR) mutations (ASXL1, EZH2, SRSF2, IDH, and U2AF1), lower JAK2V617F variant allele frequencies (VAF) have been demonstrated to be associated with poor prognosis of myelofibrosis...
2.
Refining risk prediction in pediatric acute lymphoblastic leukemia through DNA methylation profiling
Mosquera Orgueira A, Krali O, Perez Miguez C, Peleteiro Raindo A, Diaz Arias J, Gonzalez Perez M, et al.
Clin Epigenetics
. 2024 Mar;
16(1):49.
PMID: 38549146
Acute lymphoblastic leukemia (ALL) is the most prevalent cancer in children, and despite considerable progress in treatment outcomes, relapses still pose significant risks of mortality and long-term complications. To address...
3.
Mosquera Orgueira A, Perez Encinas M, Diaz Varela N, Wang Y, Mora E, Diaz-Beya M, et al.
Br J Haematol
. 2024 Feb;
204(4):1529-1535.
PMID: 38411250
Chronic myelomonocytic leukaemia (CMML) is a rare haematological disorder characterized by monocytosis and dysplastic changes in myeloid cell lineages. Accurate risk stratification is essential for guiding treatment decisions and assessing...
4.
Mosquera Orgueira A, Peleteiro Raindo A, Diaz Arias J, Antelo Rodriguez B, Lopez Rinon M, Cerchione C, et al.
Front Oncol
. 2023 Oct;
13:1302993.
PMID: 37860185
[This corrects the article DOI: 10.3389/fonc.2022.968340.].
5.
Mosquera Orgueira A, Perez Encinas M, Diaz Varela N, Mora E, Diaz-Beya M, Montoro M, et al.
Hemasphere
. 2023 Oct;
7(10):e961.
PMID: 37841754
Myelodysplastic neoplasms (MDS) are a heterogeneous group of hematological stem cell disorders characterized by dysplasia, cytopenias, and increased risk of acute leukemia. As prognosis differs widely between patients, and treatment...
6.
Bandini P, Borras N, Fernandez Mellid E, Martin-Fernandez L, Melero Valentin P, Comes N, et al.
Br J Haematol
. 2023 Sep;
203(4):e102-e107.
PMID: 37696499
No abstract available.
7.
Stuckey R, Segura-Diaz A, Saez Perdomo M, Perez Encinas M, Gonzalez San Miguel J, Florido Y, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444494
For chronic myeloid leukemia (CML) patients with a known risk of cardiovascular events (CVE), imatinib is often recommended for first-line tyrosine kinase inhibitor (TKI) treatment rather than a second-generation TKI...
8.
Mosquera Orgueira A, Diaz Arias J, Serrano Martin R, Portela Pineiro V, Cid Lopez M, Peleteiro Raindo A, et al.
Front Oncol
. 2023 May;
13:1157646.
PMID: 37188190
Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory...
9.
Mosquera Orgueira A, Peleteiro Raindo A, Cid Lopez M, Antelo Rodriguez B, Diaz Arias J, Ferreiro Ferro R, et al.
PLoS One
. 2022 Sep;
17(9):e0274984.
PMID: 36107965
[This corrects the article DOI: 10.1371/journal.pone.0247093.].
10.
Mosquera Orgueira A, Peleteiro Raindo A, Diaz Arias J, Antelo Rodriguez B, Lopez Rinon M, Cerchione C, et al.
Front Oncol
. 2022 Sep;
12:968340.
PMID: 36059646
Risk stratification in acute myeloid leukemia (AML) has been extensively improved thanks to the incorporation of recurrent cytogenomic alterations into risk stratification guidelines. However, mortality rates among fit patients assigned...